NVAX Novavax Inc

Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

$173.26  +31.40 (22.13%)
As of 12/07/2021 11:49:37 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Large cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/05/1995
Outstanding shares:  75,608,073
Average volume:  4,765,858
Market cap:   $12,133,583,555
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    670002401
ISIN:        US6700024010
Sedol:      BJDQXG4
Valuation   (See tab for details)
PE ratio:   -9.98
PB ratio:   21.94
PS ratio:   10.08
Return on equity:   -233.03%
Net income %:   -89.31%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy